Companion Animal Vaccines Market – Insights
There are two types of small companion animal vaccine available: ‘infectious’ or ‘non-infectious’ in nature. Infectious vaccines used in dogs and cats contain organisms that are attenuated to reduce virulence. Non-infectious vaccines contain an inactivated but antigenically intact virus or organism.
The global companion animal vaccines market is estimated to account for US$ 4,682.2 Mn in terms of value by the end of 2027.
Global Companion Animal Vaccines Market: Drivers
Increasing adoption of companion animals is expected to boost growth of the global companion animal vaccines market over the forecast period. For instance, according to America Veterinary Medical Association, the number of dogs in the U.S. was 76,811,305 in 2018, compared to 69,926,000 in 2012.
Moreover, increasing expenditure on animal healthcare is also expected to aid in growth of the market. For instance, according to The American Pet Products Association’s estimates in March 2018, the overall spending in the U.S. pet industry is expected to witness a 3.7% increase in 2018 compared to 2017.
Europe region held dominant position in the global companion animal vaccines market in 2019, accounting for 30.7% share in terms of value, followed by 2027.
Figure 1. Global Companion Animal Vaccines Market Share (%), by Region, 2019
Global Companion Animal Vaccines Market: Restraints
Gaps in epidemiological knowledge of certain virulent veterinary diseases is expected to hinder growth of the global companion animal vaccines market growth. There exists large gap in understanding the epidemiology pattern of veterinary diseases due to variations in disease patterns for endemic countries. For instance, Newcastle Disease for poultry and other birds. Virulent Newcastle disease virus (vNDV) is evolving simultaneously at different locations due to isolates that are distributed worldwide and mutate rapidly. This leads to large knowledge gaps on development of multiple vNDV genotypes, thereby restricting R&D of effective vaccines against Newcastle Disease.
Moreover, challenges in identifying and understanding antigen/immunogenic structures are also expected to hamper growth of the market. Such scenario leads to deficiency in fitting proper epidemiological models, thereby creating shortfall in logical representation of the epidemiology of disease transmission and its associated processes. As per marketplace discussions, veterinary research institutes need to maintain closer collaborations with vaccine manufacturers to gain deeper insights into antigen/immunogenic structures, the method through which the vaccine works and closer correlates of symptoms that could be treated with these vaccines. In this regard, manufacturers and research organizations need to create better understanding of the host immune response, protective immunity, and immunogenetics.
Global Companion Animal Vaccines Market: Opportunities
Players in the market can focused on R&D and launch of vaccines for H5N1 (Guangdong Lineage) in cats and dogs. There is no USDA-licensed vaccine for highly pathogenic avian influenza (HPAI) affecting pets (feline, canine, birds) in the U.S. The incubation time is very small, which increases the demand for immediate vaccines.
Moreover, growing awareness towards sterilization process of companion animals is also expected to offer lucrative growth opportunities for players in the market. Companion animal sterilization is an important process to control overpopulation. This in turn provides opportunity for companion animal vaccine manufacturers develop safe and effective sterilization vaccines.
Attenuated Live Vaccines segment in the global companion animal vaccines market was valued at US$ 930.6 Mn in 2019 and is expected to reach US$ 1,655.9 Mn by 2027 at a CAGR of 7.5% during the forecast period.
Market Trends/Key Takeaways
Major regulatory bodies are focused on updating guidelines related to feline retrovirus. For instance, in January 2020, The American Association of Feline Practitioners (AAFP) released updated Feline Retrovirus Testing and Management Guidelines to the veterinary community, which will be published in the Journal of Feline Medicine and Surgery.
Government and private organizations are focused on offering vaccines at lower cost. For instance, Killeen Animal Services, Texas, U.S., announced to host a low cost pet vaccination clinic in February 2020.
- The U.S. Department of Agriculture (USDA) and the Center for Veterinary Biologics (CVB) within the USDA’s Animal and Plant Health Inspection Service (APHIS) is the main group formulates regulations for veterinary biologics
- The amended version (1985) of the Virus-Serum-Toxin Act of 1913 and Title 9 of the Code of Federal Regulations (mainly sections 101–118) control the production and movement of veterinary biologics in the U.S.
- Major investigational guidelines are applied to ensure that the biologics are free of disease-producing agents and products exhibit proper safety, potency and efficacy
- The U.S. CVB also focuses on developing standards and procedures for product release, issuing licenses and permits, monitoring and inspecting products and facilities, and controlling field tests and release of veterinary biological drugs among others.
Value Chain Analysis
Global Companion Animal Vaccines Market: Competitive Landscape
Major players operating in the global companion animal vaccines market include, Bayer Healthcare, Vétoquinol S.A, Boehringer Ingelheim, Ceva Sante Animal S.A., Eli Lilly and Company (Elcano), Heska Co., Merck Animal Health, Merial (Boehringer Ingelheim),Virbac, and Zoetis.
Global Companion Animal Vaccines Market: Key Developments
Key players in the market are focused on adopting M&A strategies to expand their produxt portfolio. For instance, in January 2020, Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, acquired CVM Diagnostico Veterinario, S.L. and CVM Ecografía, S.L., providers of imaging and blood testing products to the companion animals.
Major players in the market are also focused on adopting various marketing strategies to enhance their market share. For instance, in February 2019, Boehringer Ingelheim announced to exhibit at the 2019 International Producing and Processing Expo (IPPE), with its vector vaccines Vaxxitek HVT + IBD and Newxxitek HVT + ND.